Your session is about to expire
← Back to Search
LCT + Brigatinib for Lung Cancer
Study Summary
This trial is testing the effects of LCT and brigatinib on patients with stage IV or recurrent non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had more than one treatment for my advanced cancer.I have brain metastases needing more steroids recently.I have lung conditions like interstitial disease or pneumonitis.You are allergic or have a strong sensitivity to brigatinib or any of its ingredients.I am experiencing pressure on my spinal cord.I have no other cancers except for certain skin, cervical, or treated prostate cancers.I have previously been treated with a type of medication known as TKI.Your heart's electrical activity is normal, as shown on a recent ECG test.I have a serious heart condition that is not under control.I have been diagnosed with HIV.My lung cancer is at stage IV or has come back and cannot be treated with combined therapies.I am a male and will use effective contraception or practice abstinence.I have not taken TKIs or have been on brigatinib for ≤ 8 weeks without my cancer getting worse.I am 18 years old or older.I have a condition that affects how my body absorbs medication taken by mouth.I am a woman who is either post-menopausal, surgically sterile, or using contraception.I am eligible for targeted therapy on at least one remaining cancer site.I can take care of myself and am up and about more than half of my waking hours.My blood and organ function tests are within normal ranges.I am a woman who can have children and I have a negative pregnancy test.My cancer has a specific genetic change known as ALK rearrangement.My high blood pressure is not under control.I currently have an infection.
- Group 1: Treatment (brigatinib, LCT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Local Consolidation Therapy a viable method for protecting people's wellbeing?
"As a Phase 1 trial, Local Consolidation Therapy has limited efficacy and safety data. This resulted in it receiving an overall score of 1 from Power's team evaluation."
Has Local Consolidation Therapy been explored in other research experiments?
"Currently, 11 clinical trials are exploring the effects of Local Consolidation Therapy with one study in phase 3. Although many experiments for this therapy occur in Goyang-si and Gyeonggi-do, there is a grand total of 796 medical centres conducting research on it."
Are there any vacancies for volunteers in this experiment?
"As of now, this clinical trial is not seeking participants. The first posting was recorded on December 18th 2018 and the most recent alteration occured on November 2nd 20202. However, there are 4276 studies actively recruiting patients with malignant neoplasms as well as 11 trials for Local Consolidation Therapy that require volunteers."
How many individuals have been recruited to participate in this clinical research?
"Unfortunately, this medical study is no longer admitting participants. It was first publicized on December 18th 2018 and the most recent update occurred November 2nd 2022. If you are looking for further studies to join, there are presently 4276 trials recruiting patients with malignant neoplasms plus 11 opportunities exploring Local Consolidation Therapy that still require volunteers."
Share this study with friends
Copy Link
Messenger